SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ:SQNM), a leading provider of fine mapping genotyping, methylation and gene expression analysis solutions, today announced the sales of multiple MassARRAY® systems in China. Sequenom’s new MassARRAY customers include the Beijing Genomics Institute (BGI), Asia’s largest genetic sequencing center, which plans to initially use the system for its advanced research in viral genetics and later for human genetic projects, and CapitalBio, a leading China-based life science service company with capacities for whole genome association studies, which plans to expand into the fine mapping market.

Dr. Wang Wei, BGI Director of Viral Genotyping, said, “We chose Sequenom’s MassARRAY technology because it features a unique combination of through-put, accuracy, sensitivity, reproducibility and cost efficiency. It is particularly suitable for the high-volume viral genotyping project and other population screening projects we plan to undertake in the near future.”

Sequenom’s President and CEO Harry Stylli, Ph.D. said, “We view the Chinese market as a very attractive opportunity to expand our genetic analysis business. We believe that sales to the distinguished research institute BGI and a leading service provider CapitalBio demonstrate the effectiveness of our activities to penetrate the growing Chinese market.”

About BGI

Established in 1999 and headquartered in Shenzhen, China, the Beijing Genomics Institute (BGI) is the largest genetic sequencing center in Asia. BGI has been a core participant in all major international sequencing efforts, including the International Human Genome Project and the International HapMap Consortium. The Institute has one of the largest bioinformatics teams in the world and has made a significant investment in state-of-the-art sequencing technologies, deploying more than 120 sequencing machines, 10 supercomputers, and 500 terabytes of storage. Please visit www.genomics.org.cn for more information.

About CapitalBio

CapitalBio is a leading life science company that develops and commercializes a broad range of products, including biochip technology products for drug discovery research, genomics, proteomics, bio-safety testing and clinical applications. Headquartered in Beijing, China, CapitalBio has rapidly evolved from a young innovative biochip developer into a comprehensive life science entity with five affiliates and subsidiaries: AVIVA Biosciences, a San Diego, Calif.-based company that develops and markets on-chip patch-clamp technologies for ion-channel studies for drug discovery researches; Chipscreen Biosciences, a biotech company located in Shenzhen, China, for small-molecular drug discovery and development; and CapitalBio International and CapitalBio Hong Kong, two fully owned subsidiaries by CapitalBio Corporation, are based in San Diego, Calif., and Hong Kong, China, respectively. Additional information on CapitalBio can be found at www.capitalbio.com.

About Sequenom

Sequenom is committed to providing the best genomic and genetic analysis products for research and the molecular diagnostic markets. The Company makes available superior solutions for genomic science in biomedical research, livestock and agricultural applications and molecular medicine, as well as for various diagnostic markets, including noninvasive prenatal testing, oncology and infectious diseases. Sequenom’s proprietary MassARRAY system delivers reliable and specific data from complex biological samples and from genetic target materials available only in trace amounts.

Sequenom® and MassARRAY® are trademarks of Sequenom, Inc.

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the plans of the Company’s MassARRAY system customers, expanding the Company’s genetic analysis business, and the growing Chinese market, are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with demand for and market acceptance of the Company’s products, services, and technologies, new technology and product development and commercialization, reliance upon the collaborative efforts of other parties, research and development progress, competition, government regulation, obtaining or maintaining regulatory approvals, and other risks detailed from time to time in the Company’s SEC reports, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2006 and subsequent periodic reports. These forward-looking statements are based on current information that is likely to change and speak only as of the date hereof. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Contacts
Company Contact
Sequenom, Inc.
Paul W. Hawran, Chief Financial Officer
858-202-9000
or
Investor Relations Contact
Lippert/Heilshorn & Associates
Jody Cain, 310-691-7100